Azitra Inc (AZTR) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $0.18 (+0.06%), Market cap $0.00B, 52-week low–high $0.14 ~ $1.07.
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses a
Financial statements, price targets, institutional (13F) holdings and related news for Azitra Inc are updated in real time on BlackAll Trade.
Azitra Inc trades at $0.18 (+0.06%). Real-time quotes and charts are available on BlackAll Trade.
Azitra Inc has a market cap of about $0.00B.
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases